Genetics inMedicine | CORRIGENDUM

CORRIGENDUM: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics

Sarah S. Kalia ScM, Kathy Adelman, Sherri J. Bale PhD, Wendy K. Chung MD, PhD, Christine Eng MD, James P. Evans MD, PhD, Gail E. Herman MD, PhD, Sophia B. Hufnagel MD, Teri E. Klein PhD, Bruce R. Korf MD, PhD, Kent D. McKelvey MD, Kelly E. Ormond MS, C. Sue Richards PhD, Christopher N. Vlangos PhD, Michael Watson PhD, Christa L. Martin PhD and David T. Miller MD, PhD ; on behalf of the ACMG Secondary Findings Maintenance Working Group

Genet Med advance online publication, November 17, 2016; doi:10.1038/gim.2016.190

In the published version of this article, **table 1** contained errors in the "Variants to report" column for some genes in the "Hypertrophic cardiomyopathy, dilated cardiomyopathy" and "Arrhythmogenic right ventricular cardiomyopathy" sections. Those errors have been corrected. The corrected table appears below.

Table 1 ACMG SF v2.0 genes and associated phenotypes recommended for return of secondary findings in clinical sequencing

Phenotype	MIM disorder	PMID Gene Reviews entry	Typical age of onset	Gene	MIM gene	Inheritance[a]	Variants to report[b]
Hereditary breast and ovarian cancer	604370 612555	20301425	Adult	*BRCA1* *BRCA2*	113705 600185	AD	KP and EP
Li-Fraumeni syndrome	151623	20301488	Child/adult	*TP53*	191170	AD	KP and EP
Peutz-Jeghers syndrome	175200	20301443	Child/adult	*STK11*	602216	AD	KP and EP
Lynch syndrome	120435	20301390	Adult	*MLH1* *MSH2* *MSH6* *PMS2*	120436 609309 600678 600259	AD	KP and EP
Familial adenomatous polyposis	175100	20301519	Child/adult	*APC*	611731	AD	KP and EP
MYH-associated polyposis; adenomas, multiple colorectal, *FAP* type 2; colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas	608456 132600	23035301	Adult	*MUTYH*	604933	AR[c]	KP and EP
Juvenile polyposis	174900	20301642	Child/adult	*BMPR1A* *SMAD4*	601299 600993	AD	KP and EP
Von Hippel–Lindau syndrome	193300	20301636	Child/adult	*VHL*	608537	AD	KP and EP
Multiple endocrine neoplasia type 1	131100	20301710	Child/adult	*MEN1*	613733	AD	KP and EP
Multiple endocrine neoplasia type 2	171400 162300	20301434	Child/adult	*RET*	164761	AD	KP
Familial medullary thyroid cancer[d]	1552401	20301434	Child/adult	*RET*	164761	AD	KP
PTEN hamartoma tumor syndrome	153480	20301661	Child/adult	*PTEN*	601728	AD	KP and EP
Retinoblastoma	180200	20301625	Child	*RB1*	614041	AD	KP and EP
Hereditary paraganglioma-pheochromocytoma syndrome	168000 (PGL1) 601650 (PGL2) 605373 (PGL3) 115310 (PGL4)	20301715	Child/adult	*SDHD* *SDHAF2* *SDHC* *SDHB*	602690 613019 602413 185470	AD	KP and EP KP KP and EP
Tuberous sclerosis complex	191100 613254	20301399	Child	*TSC1* *TSC2*	605284 191092	AD	KP and EP
WT1-related Wilms tumor	194070	20301471	Child	*WT1*	607102	AD	KP and EP
Neurofibromatosis type 2	101100	20301380	Child/adult	*NF2*	607379	AD	KP and EP
Ehlers-Danlos syndrome, vascular type	130050	20301667	Child/adult	*COL3A1*	120180	AD	KP and EP
Marfan syndrome, Loeys-Dietz syndromes, and familial thoracic aortic aneurysms and dissections	154700 609192 608967 610168 610380 613795 611788	20301510 20301312 20301299	Child/adult	*FBN1* *TGFBR1* *TGFBR2* *SMAD3* *ACTA2* *MYH11*	134797 190181 190182 603109 102620 160745	AD	KP and EP
Hypertrophic cardiomyopathy, dilated cardiomyopathy	115197 192600 601494 613690 115196 608751 612098 600858 301500 608758 115200	20301725	Child/adult	*MYBPC3* *MYH7* *TNNT2* *TNNI3* *TPM1* *MYL3* *ACTC1* *PRKAG2* *GLA* *MYL2* *LMNA*	600958 160760 191045 191044 191010 160790 102540 602743 300644 160781 150330	AD XL AD	KP and EP KP KP and EP KP KP and EP (hemi, het, hom) KP KP and EP
Catecholaminergic polymorphic ventricular tachycardia	604772			*RYR2*	180902	AD	KP
Arrhythmogenic right ventricular cardiomyopathy	609040 604400 610476 607450 610193	20301310	Child/adult	*PKP2* *DSP* *DSC2* *TMEM43* *DSG2*	602861 125647 125645 612048 125671	AD	KP and EP KP KP and EP
Romano-Ward long-QT syndrome types 1, 2, and 3, Brugada syndrome	192500 613688 603830 601144	20301308	Child/adult	*KCNQ1* *KCNH2* *SCN5A*	607542 152427 600163	AD	KP and EP
Familial hypercholesterolemia	143890 603776	24404629	Child/adult	*LDLR* *APOB* *PCSK9*	606945 107730 607786	SD SD AD	KP and EP KP
Wilson disease	277900	20301685	Child	*ATP7B*	606882	AR[c]	KP and EP
Ornithine transcarbamylase deficiency	311250	24006547	Newborn (male), child (female)	*OTC*	300461	XL	KP and EP (hemi, het, hom)
Malignant hyperthermia susceptibility	145600	20301325	Child/adult	*RYR1* *CACNA1S*	180901 114208	AD	KP

[a]Some conditions that may demonstrate semidominant inheritance have been indicated as autosomal-dominant (AD) for the sake of simplicity. Others have been labeled as X-linked (XL). [b]KP: known pathogenic, sequence variation is previously reported and is a recognized cause of the disorder; EP: expected pathogenic, sequence variation is previously unreported and is of the type that is expected to cause the disorder. Note: The recommendation to not report expected pathogenic variants for some genes is due to the recognition that truncating variants, the primary type of expected pathogenic variants, are not an established cause of some diseases on the list. [c]We recommend searching only for individuals with biallelic mutations.